Patents by Inventor Friedrich Götz

Friedrich Götz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7462476
    Abstract: The invention belongs to the field of thrombolysis and of tissue plasminogen activator (tPA) derivative production in prokaryotic cells. The invention relates to methods for the production of a recombinant DNA-derived tPA, a variant thereof or a (Kringle 2 Serine) K2S molecule or a variant thereof in prokaryotic cells, wherein the tPA or K2S or variant is secreted extracellularly as an active and correctly folded protein, and the prokaryotic cell contains and expresses a vector comprising the DNA coding for the tPA or K2S or variant operably linked to the DNA coding for the signal peptide OmpA. The invention further relates to specific K2S derivatives obtainable by the method. The invention further relates to the DNA molecules and the use of the DNA molecules in the methods.
    Type: Grant
    Filed: May 23, 2005
    Date of Patent: December 9, 2008
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Jiradej Manosroi, Aranya Manosroi, Chatchai Tayapiwatana, Friedrich Goetz, Rolf-Guenther Werner
  • Patent number: 7087412
    Abstract: The invention belongs to the field of protein production in prokaryotic cells. The invention relates to methods for the production of recombinant DNA-derived heterologous protein in prokaryotic cells, wherein the heterologous protein is secreted extracellularly as an active and correctly folded protein, and the prokaryotic cell contains and expresses a vector comprising the DNA coding for the heterologous protein operably linked to the DNA coding for the signal peptide OmpA.
    Type: Grant
    Filed: November 14, 2001
    Date of Patent: August 8, 2006
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Jiradej Manosroi, Aranya Manosroi, Chatchai Tayapiwatana, Friedrich Goetz, Rolf-Guenther Werner
  • Patent number: 6955910
    Abstract: The invention belongs to the field of thrombolysis and of tissue plasminogen activator (tPA) derivative production in prokaryotic cells. The invention relates to methods for the production of a recombinant DNA-derived tPA, a variant therof or a (Kringle 2 Serine) K2S molecule or a variant therof in prokaryotic cells, wherein the tPA or K2S or variant is secreted extracellularly as an active and correctly folded protein, and the prokaryotic cell contains and expresses a vector comprising the DNA coding for the tPA or K2S or variant operably linked to the DNA coding for the signal peptide OmpA. The invention further relates to specific K2S derivatives obtainable by the method. The invention further relates to the DNA molecules and the use of the DNA molecules in the methods.
    Type: Grant
    Filed: November 14, 2001
    Date of Patent: October 18, 2005
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Jiradej Manosroi, Aranya Manosroi, Chatchai Tayapiwatana, Friedrich Goetz, Rolf-Guenther Werner
  • Publication number: 20050202040
    Abstract: The invention belongs to the field of thrombolysis and of tissue plasminogen activator (tPA) derivative production in prokaryotic cells. The invention relates to methods for the production of a recombinant DNA-derived tPA, a variant therof or a (Kringle 2 Serine) K2S molecule or a variant therof in prokaryotic cells, wherein the tPA or K2S or variant is secreted extracellularly as an active and correctly folded protein, and the prokaryotic cell contains and expresses a vector comprising the DNA coding for the tPA or K2S or variant operably linked to the DNA coding for the signal peptide OmpA. The invention further relates to specific K2S derivatives obtainable by the method. The invention further relates to the DNA molecules and the use of the DNA molecules in the methods.
    Type: Application
    Filed: May 23, 2005
    Publication date: September 15, 2005
    Applicant: Boehringer Ingelheim International GmbH
    Inventors: Jiradej Manosroi, Aranya Manosroi, Chatchai Tayapiwatana, Friedrich Goetz, Rolf-Guenther Werner
  • Patent number: 6821755
    Abstract: The invention relates to advantageous processes for preparing heterologous proteins in prokaryotic host cells by improved codon use and/or expression of tRNAs which code for codons occurring rarely in said host cell.
    Type: Grant
    Filed: July 27, 2001
    Date of Patent: November 23, 2004
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Rolf-Günther Werner, Klaus Bergemann, Friedrich Götz, Andreas Peschel
  • Patent number: 6660835
    Abstract: The present invention relates to peptides, which are useful in treating Staphylococcus infections. More particularly, the inventive peptides interfere with the regulation of the agr system of Staphylococcus species, especially S. aureus, and thereby block the formation of different virulence factors. The inventive peptides comprise at least the amino acid sequence S V X A S Y F, whereby cyclic structures of that kind of peptides are the most potent blocking reagents.
    Type: Grant
    Filed: December 24, 1998
    Date of Patent: December 9, 2003
    Inventors: Michael Otto, Roderich Suessmuth, Guenther Jung, Friedrich Goetz
  • Patent number: 6566062
    Abstract: A method for identifying a nucleic acid which codes for a polypeptide factor affecting the covalent bonding of polypeptides to the surface of Gram-positive bacteria, comprising the following steps: a) providing a sample of Gram-positive bacteria which can be genetically altered and contain or produce at least one enzymatic reporter substance which is or can become covalently bonded to the surface of the Gram-positive bacteria, said at least one reporter substance having a different enzymatic activity when not covalently bonded to the surface of the Gram-positive bacteria from that exhibited when it is covalently bonded to the surface of the Gram-positive bacteria; b) causing genetic alterations in Gram-positive bacteria of the sample; c) assaying the enzymatic activity of the reporter substance of the Gram-positive bacteria of the sample; d) separating Gram-positive bacteria which exhibit a different enzymatic activity of the reporter substance from that observed for covalent bonding of the reporter subst
    Type: Grant
    Filed: May 2, 2000
    Date of Patent: May 20, 2003
    Assignee: Evotec BioSystems AG
    Inventors: Andreas Strauss, Gunther Thumm, Johannes Pohlner, Friedrich Götz
  • Publication number: 20030049729
    Abstract: The invention belongs to the field of thrombolysis and of tissue plasminogen activator (tPA) derivative production in prokaryotic cells. The invention relates to methods for the production of a recombinant DNA-derived tPA, a variant therof or a (Kringle 2 Serine) K2S molecule or a variant therof in prokaryotic cells, wherein the tPA or K2S or variant is secreted extracellularly as an active and correctly folded protein, and the prokaryotic cell contains and expresses a vector comprising the DNA coding for the tPA or K2S or variant operably linked to the DNA coding for the signal peptide OmpA. The invention further relates to specific K2S derivatives obtainable by the method. The invention further relates to the DNA molecules and the use of the DNA molecules in the methods.
    Type: Application
    Filed: November 14, 2001
    Publication date: March 13, 2003
    Inventors: Jiradej Manosroi, Aranya Manosroi, Chatchai Tayapiwatana, Friedrich Goetz, Rolf-Guenther Werner
  • Publication number: 20030013150
    Abstract: The invention belongs to the field of protein production in prokaryotic cells. The invention relates to methods for the production of recombinant DNA-derived heterologous protein in prokaryotic cells, wherein the heterologous protein is secreted extracellularly as an active and correctly folded protein, and the prokaryotic cell contains and expresses a vector comprising the DNA coding for the heterologous protein operably linked to the DNA coding for the signal peptide OmpA.
    Type: Application
    Filed: November 14, 2001
    Publication date: January 16, 2003
    Inventors: Jiradej Manosroi, Aranya Manosroi, Chatchai Tayapiwatana, Friedrich Goetz, Rolf-Guenther Werner
  • Patent number: 5162221
    Abstract: A fructose-1,6-bisphosphate aldolase with obtained from Staphylococcus carnosus is disclosed. The aldolase has considerably improved stability as compared to aldolase from rabbit muscle, having an inactivation rate of 0.77%/d at 25.degree. C. as compared with 59.3%/d for rabbit muscle aldolase. The aldolase is obtained by culturing Staphylococcus carnosus cells, mechanically disrupting the cell mass, and then working up the product by fractional ammonium sulfate precipitation, pH fractionation and ion exchange chromatography to provide F-1,6-BP aldolase with a specific activity of 25 U/mg in 21% yield. Particularly high yields are obtained by the aqueous 2-phase extraction and obtaining the enzyme from the upper phase by anion exchange chromatography. The aldolase is suitable for synthesis of carbohydrates and derivatives thereof by enzymatic reaction of aldehydes with DHAP.
    Type: Grant
    Filed: December 7, 1990
    Date of Patent: November 10, 1992
    Assignee: Forschungszentrum Juelich GmbH
    Inventors: Hans-Peter Brockamp, Maria-Regina Kula, Friedrich Goetz